YAHOO FINANCE CHARTBOOK

44 charts that explain markets and the economy right now

HKSE - Delayed Quote HKD

JW (Cayman) Therapeutics Co. Ltd (2126.HK)

1.390

-0.010

(-0.71%)

At close: 11:34:08 AM GMT+8

$JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma$

JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma

JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China (NMPA) granted Breakthrough Therapy Designation for Carteyva® (relmacabtagene autoleucel injection) as second-line treatment in adults with relapsed or refractory large B-cell lymphoma (r/r LBCL) . Carteyva® is an anti-CD19

PR Newswire 18 days ago

JWCTF
Gulf Pharmaceutical Industries P.S.C And 2 Other Promising Penny Stocks

As global markets continue to show mixed results, with major U.S. indexes like the S&P 500 and Nasdaq Composite reaching record highs while others such as the Russell 2000 decline, investors are increasingly looking at diverse investment opportunities. Penny stocks, despite their somewhat outdated name, remain a compelling area for those interested in smaller or newer companies that may offer surprising value. By focusing on stocks with solid financial foundations and potential for growth,...

Simply Wall St. last month

PTEXF

JWCTF
$JW Therapeutics Announces NMPA Approval of the Supplemental Biological License Application for Carteyva® in Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma$

JW Therapeutics Announces NMPA Approval of the Supplemental Biological License Application for Carteyva® in Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma

JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) of China has approved the supplemental Biological License Application (sBLA) for its anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product Carteyva® (relmacabtagene autoleucel injection) for the treatment of adult patients with relaps

PR Newswire 4 months ago

JWCTF
Preliminary Clinical Data on Relma-Cel Injection in Adults with Active Systemic Lupus Erythematosus in China at the Eular 2024 Congress

JW (Cayman) Therapeutics Co. Ltd (the "Company" or "JW Therapeutics", together with its subsidiaries, the "Group"), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, presented the preliminary clinical data on relmacabtagene autoleucel ("relma-cel") injection in adults with active systemic lupus erythematosus ("SLE") in China at the 2024 European Alliance of Associations for Rheumatology Congress ("EULAR 2024"

PR Newswire 7 months ago

JWCTF

Performance Overview

Return	2126.HK	HANG SENG INDEX
YTD	+5.30%	+0.92%
1-Year	-28.72%	+26.79%
3-Year	-85.09%	-15.05%